Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:HRMY NASDAQ:IOVA NASDAQ:NRIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$4.26-3.2%$3.54$1.39▼$4.60$486.50M2.922.51 million shs20.14 million shsHRMYHarmony Biosciences$35.47+3.9%$31.96$25.52▼$40.87$1.98B0.96771,938 shs1.77 million shsIOVAIovance Biotherapeutics$4.25+1.0%$3.85$1.66▼$5.63$1.88B0.7413.06 million shs23.69 million shsNRIXNurix Therapeutics$22.90+2.0%$16.98$8.19▼$23.72$2.32B1.863.45 million shs6.49 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+3.53%+6.54%+26.07%+82.57%+185.71%HRMYHarmony Biosciences-0.93%+2.55%+13.43%+28.60%+8.11%IOVAIovance Biotherapeutics-0.85%+7.65%+2.68%+19.94%+136.52%NRIXNurix Therapeutics+16.37%+27.98%+29.23%+52.17%+93.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$4.26-3.2%$3.54$1.39▼$4.60$486.50M2.922.51 million shs20.14 million shsHRMYHarmony Biosciences$35.47+3.9%$31.96$25.52▼$40.87$1.98B0.96771,938 shs1.77 million shsIOVAIovance Biotherapeutics$4.25+1.0%$3.85$1.66▼$5.63$1.88B0.7413.06 million shs23.69 million shsNRIXNurix Therapeutics$22.90+2.0%$16.98$8.19▼$23.72$2.32B1.863.45 million shs6.49 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+3.53%+6.54%+26.07%+82.57%+185.71%HRMYHarmony Biosciences-0.93%+2.55%+13.43%+28.60%+8.11%IOVAIovance Biotherapeutics-0.85%+7.65%+2.68%+19.94%+136.52%NRIXNurix Therapeutics+16.37%+27.98%+29.23%+52.17%+93.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.57Moderate Buy$7.7581.92% UpsideHRMYHarmony Biosciences 2.27Hold$40.8915.28% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.4398.32% UpsideNRIXNurix Therapeutics 2.81Moderate Buy$32.2040.61% UpsideCurrent Analyst Ratings BreakdownLatest CCCC, HRMY, IOVA, and NRIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026HRMYHarmony Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/18/2026NRIXNurix Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$26.00 ➝ $33.006/15/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.006/10/2026NRIXNurix Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.006/9/2026NRIXNurix Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.006/8/2026NRIXNurix Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.006/8/2026NRIXNurix Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Hold$28.00 ➝ $25.006/8/2026NRIXNurix Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $45.006/8/2026NRIXNurix Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$26.00 ➝ $34.005/22/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.95M13.10N/AN/A$2.65 per share1.61HRMYHarmony Biosciences$868.45M2.36$3.31 per share10.73$15.11 per share2.35IOVAIovance Biotherapeutics$263.50M7.20N/AN/A$1.76 per share2.41NRIXNurix Therapeutics$83.98M28.20N/AN/A$5.29 per share4.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4814.309.740.2416.20%17.19%11.99%8/4/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)NRIXNurix Therapeutics-$264.46M-$3.16N/AN/AN/A-411.37%-64.21%-48.44%7/9/2026 (Estimated)Latest CCCC, HRMY, IOVA, and NRIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/9/2026Q2 2026NRIXNurix Therapeutics-$0.73N/AN/AN/A$15.29 millionN/A5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million4/8/2026Q1 2026NRIXNurix Therapeutics-$0.76-$0.79-$0.03-$0.79$14.25 million$6.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A9.009.00HRMYHarmony Biosciences0.153.583.56IOVAIovance BiotherapeuticsN/A3.603.15NRIXNurix TherapeuticsN/A6.016.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%HRMYHarmony Biosciences86.23%IOVAIovance Biotherapeutics77.03%NRIXNurix TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics5.60%HRMYHarmony Biosciences11.00%IOVAIovance Biotherapeutics7.80%NRIXNurix Therapeutics6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableNRIXNurix Therapeutics300103.41 million96.48 millionOptionableCCCC, HRMY, IOVA, and NRIX HeadlinesRecent News About These CompaniesNurix Stock Up 29% in a Month: Here's What You Should KnowJune 26 at 12:05 PM | zacks.comNurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?June 26 at 11:45 AM | zacks.comNurix Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:NRIXJune 26 at 9:24 AM | benzinga.comNurix (NRIX) Climbs to 52-Week High — This Deal May Hold the AnswerJune 26 at 9:24 AM | finance.yahoo.comNurix Therapeutics (NASDAQ:NRIX) Insider Sells 5,394 SharesJune 26 at 6:07 AM | insidertrades.comNurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year High - Should You Buy?June 26 at 4:03 AM | americanbankingnews.com5 Stocks Winning by Double DigitsJune 25 at 10:22 PM | insidermonkey.comFlax Pond Capital LLC Invests $1.52 Million in Nurix Therapeutics, Inc. $NRIXJune 20, 2026 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from AnalystsJune 20, 2026 | americanbankingnews.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 20, 2026 | marketbeat.comPerceptive Advisors LLC Buys 2,139,728 Shares of Nurix Therapeutics, Inc. $NRIXJune 18, 2026 | marketbeat.comElmind Capital LP Takes $8.73 Million Position in Nurix Therapeutics, Inc. $NRIXJune 18, 2026 | marketbeat.comNurix Therapeutics, Inc. $NRIX Shares Sold by Commodore Capital LPJune 18, 2026 | marketbeat.comNurix Therapeutics, Inc. $NRIX Position Boosted by Baker BROS. Advisors LPJune 18, 2026 | marketbeat.comGeneral Atlantic L.P. Buys Shares of 4,897,159 Nurix Therapeutics, Inc. $NRIXJune 17, 2026 | marketbeat.comZyVersa Therapeutics (NASDAQ:ZVSA) vs. Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head AnalysisJune 17, 2026 | americanbankingnews.comNurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst TargetJune 16, 2026 | finance.yahoo.comTruist is Bullish on Nurix Therapeutics, Inc. (NRIX)June 16, 2026 | finance.yahoo.comTruist is Bullish on Nurix Therapeutics, Inc. (NRIX)June 16, 2026 | insidermonkey.comNeedham & Company LLC Reaffirms Buy Rating for Nurix Therapeutics (NASDAQ:NRIX)June 15, 2026 | marketbeat.comRhenman & Partners Asset Management AB Increases Stock Position in Nurix Therapeutics, Inc. $NRIXJune 13, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCCC, HRMY, IOVA, and NRIX Company DescriptionsC4 Therapeutics NASDAQ:CCCC$4.26 -0.14 (-3.18%) Closing price 04:00 PM EasternExtended Trading$4.39 +0.13 (+3.15%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Harmony Biosciences NASDAQ:HRMY$35.47 +1.34 (+3.93%) Closing price 04:00 PM EasternExtended Trading$35.34 -0.13 (-0.35%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Iovance Biotherapeutics NASDAQ:IOVA$4.25 +0.04 (+0.95%) Closing price 04:00 PM EasternExtended Trading$4.24 -0.01 (-0.24%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Nurix Therapeutics NASDAQ:NRIX$22.90 +0.44 (+1.96%) Closing price 04:00 PM EasternExtended Trading$22.35 -0.55 (-2.40%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
